ATXS News

Latest breaking news and updates for ATXS stock.

Track all markets on TradingView

Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported fin...

Are there any upcoming catalysts (e.g., data readouts, conference presentations) that could drive short‑term volatility in the stock? What is the projected impact of the Q2 results on the company's long‑term growth trajectory and market positioning? How might the recent corporate update influence analyst coverage, target price revisions, and market sentiment toward ATXS?
Earnings
15 days ago
Read more businesswire

Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced th...

What should traders monitor in upcoming earnings calls or FDA updates for signs of progress or setbacks on navenibart's development? Does the exclusive Japan rights agreement limit Astria's ability to license navenibart in other Asian markets, and what are the strategic implications? How will this licensing partnership influence Astria Therapeutics' valuation multiples relative to peers?
Licensing
21 days ago
Read more businesswire

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock opti...

How does the size of this grant (180,000 shares) compare to the company’s average daily trading volume? Are there any anti‑dilution provisions or protective clauses tied to these options that could impact future financing activities? Will the grant affect the company’s ability to meet Nasdaq’s listing requirements in the near term?
Finance
23 days ago
Read more businesswire